Johnson & Johnson Reports Five-Year MAIA Data for Darzalex in Newly Diagnosed Myeloma

Johnson & Johnson today presented five-year overall survival data from the Phase 3 MAIA trial evaluating Darzalex (daratumumab) plus lenalidomide and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in patients with newly diagnosed multiple myeloma who were ineligible for autologous stem cell transplantation. The data showed a significant improvement in overall survival with DRd, with a median overall survival not reached in the DRd arm compared to 56.2 months in the Rd arm.